These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

856 related items for PubMed ID: 19622757

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E, Azuma Y, Saito H, Tsunenari T, Watanabe T, Hirabayashi M, Sato K, Yamada-Okabe H, Ogata E.
    Clin Cancer Res; 2005 Jun 01; 11(11):4198-203. PubMed ID: 15930357
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pathophysiology and management of severe hypercalcemia.
    Nussbaum SR.
    Endocrinol Metab Clin North Am; 1993 Jun 01; 22(2):343-62. PubMed ID: 8325291
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Malignancy-related hypercalcemia developing on a bisphosphonate but responding to calcitonin.
    Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB.
    Clin Lung Cancer; 2007 Jul 01; 8(7):434-5. PubMed ID: 17681097
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms and treatment of hypercalcemia of malignancy.
    Clines GA.
    Curr Opin Endocrinol Diabetes Obes; 2011 Dec 01; 18(6):339-46. PubMed ID: 21897221
    [Abstract] [Full Text] [Related]

  • 10. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
    Sekine M, Takami H.
    Oncol Rep; 1998 Dec 01; 5(1):197-9. PubMed ID: 9458321
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Treatment of malignancy-associated hypercalcemia].
    Endo I, Inoue D.
    Clin Calcium; 2006 Apr 01; 16(4):665-69. PubMed ID: 16582519
    [Abstract] [Full Text] [Related]

  • 13. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
    Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP.
    Cancer J; 2006 Apr 01; 12(1):47-53. PubMed ID: 16613662
    [Abstract] [Full Text] [Related]

  • 14. Hypercalcemia: an evidence-based approach to clinical cases.
    Assadi F.
    Iran J Kidney Dis; 2009 Apr 01; 3(2):71-9. PubMed ID: 19395781
    [Abstract] [Full Text] [Related]

  • 15. Medical treatment of hypercalcemia.
    Schaiff RA, Hall TG, Bar RS.
    Clin Pharm; 1989 Feb 01; 8(2):108-21. PubMed ID: 2521820
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor.
    Van den Eynden GG, Neyret A, Fumey G, Rizk-Rabin M, Vermeulen PB, Bouizar Z, Body JJ, Dirix LY.
    Bone; 2007 Apr 01; 40(4):1166-71. PubMed ID: 17188588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.